Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16528516 | 1.00 | EPHX1 (0.47) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| SCHEMBL1062309 | 1.00 | EPHX1 (0.47) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| SCHEMBL145280 | 0.95 | EPHX1 (0.44) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| SCHEMBL1268688 | 0.95 | EPHX1 (0.44) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| SCHEMBL79825 | 0.95 | EPHX1 (0.44) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL2417195 | 0.94 | EPHX1 (0.43) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL2422106 | 0.94 | EPHX1 (0.43) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| Formic Acid Methyl Ester SCHEMBL28113367 | 0.92 | EPHX1 (0.41) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| Formic Acid Methyl Ester SCHEMBL28113507 | 0.92 | EPHX1 (0.41) | EPHX1SCN9ACYP1A2CYP2D6LMNA | |
| Formic Acid Methyl Ester SCHEMBL28112856 | 0.92 | EPHX1 (0.41) | EPHX1SCN9ACYP1A2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388533-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS | CONCENTRIC ANALGESICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12378199-B2 | Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules | UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “A. AVOGADRO” (IT) | 2025-08-05 | — | — | US | disclosed |
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| EP-3941899-B1 | RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES | UNIV DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO (IT) | 2024-07-03 | — | — | EP | disclosed |
| EP-3941899-B1 | RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES | UNIV DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO (IT) | 2024-07-03 | — | — | EP | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| EP-1289955-B1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2005-04-13 | — | — | EP | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004014370-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| US-6677354-B2 | TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1289955-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096302-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-12-20 | — | — | WO | disclosed |
| US-5189046-A | Antiinflammatory agents, anticonvulsants | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-02-23 | — | — | US | disclosed |
| WO-1992003415-A1 | PROTEIN KINASE C MODULATORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | GRM5, GRIK5, GRM1 | EPHX1 888/4885SCN9A 1171/4885CYP1A2 1064/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | EPHX1 1415/4885SCN9A 211/4885CYP1A2 98/4885 |
| US-20250388533-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS | TRPV1, TRPV3, TRPV4 | EPHX1 2273/4885SCN9A 271/4885CYP1A2 701/4885 |
| US-12378199-B2 | Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules | SLC29A1, APRT, SLC29A2 | EPHX1 4722/4885SCN9A 4299/4885CYP1A2 4754/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885SCN9A 4703/4885CYP1A2 3570/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | EPHX1 2442/4885SCN9A 4502/4885CYP1A2 4056/4885 |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | HCRTR2, HCRTR1, NPSR1 | EPHX1 1942/4885SCN9A 218/4885CYP1A2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.